Cabenuva (cabotegravir/rilpivirine) – New indication
March 29, 2022 - ViiV Healthcare announced the FDA approval of Cabenuva (cabotegravir/rilpivirine), as a complete regimen for the treatment of human immunodeficiency virus (HIV)-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA < 50 copies/mL) on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine.
Top